Trial ID: | L0153 |
Source ID: | NCT00112008
|
Associated Drug: |
De Novo Administration Of Darbepoetin Alfa
|
Title: |
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
|
Acronym: |
|
Status: |
COMPLETED
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Chronic Kidney Disease|Kidney Disease
|
Interventions: |
DRUG: De Novo Administration of Darbepoetin Alfa
|
Outcome Measures: |
Primary: The proportion of subjects achieving a Hb ≥ 11.0 g/dL, Entire Study | Secondary: Hb values over the duration of the study, Entire Study|Darbepoetin alfa doses over the duration of the study, Entire Study|Frequency, severity, and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure, Entire Study
|
Sponsor/Collaborators: |
Sponsor: Amgen
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE3
|
Enrollment: |
100
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2004-05
|
Completion Date: |
2005-03
|
Results First Posted: |
|
Last Update Posted: |
2009-07-10
|
Locations: |
|
URL: |
https://clinicaltrials.gov/show/NCT00112008
|